Anti-CCR7 therapy exerts a potent anti-tumor activity in a xenograft model of human mantle cell lymphoma
OPEN Journal of hematology & oncology | 7 Dec 2013
B Somovilla-Crespo, M Alfonso-Pérez, C Cuesta-Mateos, C Carballo-de Dios, AE Beltrán, F Terrón, JJ Pérez-Villar, C Gamallo-Amat, G Pérez-Chacón, E Fernández-Ruiz, JM Zapata and C Muñoz-Calleja
The chemokine receptor CCR7 mediates lymphoid dissemination of many cancers, including lymphomas and epithelial carcinomas, thus representing an attractive therapeutic target. Previous results have highlighted the potential of the anti-CCR7 monoclonal antibodies to inhibit migration in transwell assays. The present study aimed to evaluate the in vivo therapeutic efficacy of an anti-CCR7 antibody in a xenografted human mantle cell lymphoma model.
* Data courtesy of Altmetric.com